Aptahem enters a collaboration with University Health Network in Canada to test Apta-1 in a coronavirus model
Aptahem (publ) today announced the beginning of a collaboration with the University Health Network, a research hospital affiliated with University of Toronto in Canada. The collaboration aims to evaluate the anti-coagulant Apta-1 as an inhibitor of hyper inflammatory response and an inducer of tissue repair to potentially treat COVID-19 disease.The research team in Canada, led by Professor Mingyao Liu, has developed a unique murine coronavirus-induced acute lung injury model to study SARS with pathological features shared between SARS and COVID-19. This is the only in vivo model of its kind